Since IFN-α and IFN-β are widely used to treat hepatitis B virus and hepatitis C virus infections [30], USP18 inhibitors may be an effective strategy for modulating IFN antiviral activity. This evidence concerns the gene IFNB1 and hepatitis C virus infection.